Clinical Trial

Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer

Study acronym: LALEAST
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 15, 2023 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Phase II trial of 2 years of standard adjuvant endocrine therapy after low risk hormone receptor positive, HER2 negative, node negative breast cancer in women older than 50 at diagnosis. The study hypothesis is that reducing adjuvant endocrine therapy from 5 to 2 years in a population with low risk of breast cancer; as determined by histopathologic criteria and confirmed by low risk genomic analysis using Prosigna®; will be safe and acceptable to this population, and will not compromise the expected excellent breast cancer specific outcomes for this population.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-04-12; most recent amendment 2023-06-13.
Status change: Recruiting → Active, Not Recruiting 2023-06-13
Status change: Not Yet Recruiting → Recruiting 2020-12-07
Trial Details
NCT Number NCT03917082
Lead Sponsor British Columbia Cancer Agency
Collaborators: Canadian Cancer Society (CCS), NanoString Technologies, Inc.
Conditions Breast Cancer Female, Hormone Receptor Positive Tumor
Enrollment 290 participants
Start Date 2019-09-23
Primary Completion 2026-05-01 (estimated)
Study Completion 2029-05-01 (estimated)
Updated on ClinicalTrials.gov 2023-06-15